Pub Date : 2026-01-27DOI: 10.1016/s2352-3018(26)00011-1
Tony Kirby
{"title":"Using art to promote HIV prevention and highlight inequalities","authors":"Tony Kirby","doi":"10.1016/s2352-3018(26)00011-1","DOIUrl":"https://doi.org/10.1016/s2352-3018(26)00011-1","url":null,"abstract":"","PeriodicalId":48725,"journal":{"name":"Lancet Hiv","volume":"36 1","pages":""},"PeriodicalIF":16.1,"publicationDate":"2026-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146071544","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-15DOI: 10.1016/s2352-3018(25)00232-2
Eugene Kinyanda,Leticia Kyohangirwe,Richard S Mpango,Isaac Sekitoleko,Wilber Ssembajjwe,Christine Tusiime,Joshua Ssebunnya,Kenneth Katumba,Barbra Elsa Kiconco,Yoko Laurence,Patrick Tenya,Joy Turyahabwa,Patrick Katana,Ian Ross,Anna Vassall,Giulia Greco,James Mugisha,Geoffrey Taasi,Hafsa Sentongo,Dickens Akena,Wilson W Muhwezi,Helen A Weiss,Melissa Neuman,Birthe L Knizek,Jonathan Levin,Pontiano Kaleebu,Ricardo Araya,Vikram Patel
BACKGROUNDAlthough depression is common in people with HIV, mental health interventions are not available to the vast majority of people with HIV in Africa. We aimed to test the effectiveness of the HIV+D collaborative stepped care depression intervention in adult HIV care in Uganda.METHODSA cluster-randomised controlled trial was done at 40 randomly selected primary HIV care centres (clusters) at public health-care facilities in three districts in Uganda. The 40 clusters were randomly allocated (1:1) to enhanced usual care only (EUC arm) or to HIV+D intervention plus EUC, with the randomisation stratified by level of health facility. We recruited adults (aged 18 years or older) with HIV with depression, defined by the locally validated version of the Patient Health Questionnaire 9 (PHQ-9). Participants were consecutively recruited into the study clinics until there was a maximum of 30 participants per cluster. HIV+D was coordinated by a lay counsellor and involved four sequential steps of psychoeducation, behavioural activation, antidepressant medication, and referral. EUC comprised sharing screening results with the HIV clinic physician and training on the WHO guidelines for depression management in routine care. The primary outcome was PHQ-9 scores at 3 months. The trial is registered with the ISRCTN registry (ISRCTN86760765) and is completed.FINDINGS8441 people with HIV were referred to the trial, and 1115 (13%) were enrolled between May 3 and Dec 31, 2021. The mean age was 38 years, 859 (77%) were female, 535 were enrolled in the EUC group, and 580 were enrolled in the HIV+D plus EUC group. Primary outcome data were available for 1097 (98%) participants. We observed high levels of fidelity, with 290 (92%) of 316 participants in the HIV+D plus EUC intervention group receiving the recommended 4-10 sessions of behavioural activation. At 3 months, the mean PHQ-9 scores were lower in the HIV+D plus EUC group, at 3middot;0 (SD 3middot;2) compared with the EUC group, at 7middot;6 (SD 4middot;2; adjusted mean difference 4middot;4; 95% CI 3middot;4-5middot;5; p<0middot;0001; effect size [d]=1middot;34). This effect was sustained, although attenuated, at 12 months (adjusted mean difference 1middot;9; 95% CI 1middot;0-2middot;8; p<0middot;0001; d=0middot;81). Baseline depression severity scores moderated the HIV+D plus EUC intervention effect, with the intervention having stronger effects for those with baseline scores in the severe range (≥20) than for those whose scores were in the moderate range (10-19) both at 3 and 12 months (p values for effect modification were <0middot;001 and 0middot;005, respectively). There was no evidence of effect modification by sex nor baseline HIV viral load. One participant in the HIV+D plus EUC group was hospitalised because of severe depression.INTERPRETATIONThe HIV+D plus EUC intervention had a significant and sustained effect on depression compared with EUC. This intervention offers a scalable approach to integrate
{"title":"Assessing the effectiveness of a depression-integrated model in adult HIV care in Uganda (the HIV+D trial): a cluster-randomised controlled trial.","authors":"Eugene Kinyanda,Leticia Kyohangirwe,Richard S Mpango,Isaac Sekitoleko,Wilber Ssembajjwe,Christine Tusiime,Joshua Ssebunnya,Kenneth Katumba,Barbra Elsa Kiconco,Yoko Laurence,Patrick Tenya,Joy Turyahabwa,Patrick Katana,Ian Ross,Anna Vassall,Giulia Greco,James Mugisha,Geoffrey Taasi,Hafsa Sentongo,Dickens Akena,Wilson W Muhwezi,Helen A Weiss,Melissa Neuman,Birthe L Knizek,Jonathan Levin,Pontiano Kaleebu,Ricardo Araya,Vikram Patel","doi":"10.1016/s2352-3018(25)00232-2","DOIUrl":"https://doi.org/10.1016/s2352-3018(25)00232-2","url":null,"abstract":"BACKGROUNDAlthough depression is common in people with HIV, mental health interventions are not available to the vast majority of people with HIV in Africa. We aimed to test the effectiveness of the HIV+D collaborative stepped care depression intervention in adult HIV care in Uganda.METHODSA cluster-randomised controlled trial was done at 40 randomly selected primary HIV care centres (clusters) at public health-care facilities in three districts in Uganda. The 40 clusters were randomly allocated (1:1) to enhanced usual care only (EUC arm) or to HIV+D intervention plus EUC, with the randomisation stratified by level of health facility. We recruited adults (aged 18 years or older) with HIV with depression, defined by the locally validated version of the Patient Health Questionnaire 9 (PHQ-9). Participants were consecutively recruited into the study clinics until there was a maximum of 30 participants per cluster. HIV+D was coordinated by a lay counsellor and involved four sequential steps of psychoeducation, behavioural activation, antidepressant medication, and referral. EUC comprised sharing screening results with the HIV clinic physician and training on the WHO guidelines for depression management in routine care. The primary outcome was PHQ-9 scores at 3 months. The trial is registered with the ISRCTN registry (ISRCTN86760765) and is completed.FINDINGS8441 people with HIV were referred to the trial, and 1115 (13%) were enrolled between May 3 and Dec 31, 2021. The mean age was 38 years, 859 (77%) were female, 535 were enrolled in the EUC group, and 580 were enrolled in the HIV+D plus EUC group. Primary outcome data were available for 1097 (98%) participants. We observed high levels of fidelity, with 290 (92%) of 316 participants in the HIV+D plus EUC intervention group receiving the recommended 4-10 sessions of behavioural activation. At 3 months, the mean PHQ-9 scores were lower in the HIV+D plus EUC group, at 3middot;0 (SD 3middot;2) compared with the EUC group, at 7middot;6 (SD 4middot;2; adjusted mean difference 4middot;4; 95% CI 3middot;4-5middot;5; p<0middot;0001; effect size [d]=1middot;34). This effect was sustained, although attenuated, at 12 months (adjusted mean difference 1middot;9; 95% CI 1middot;0-2middot;8; p<0middot;0001; d=0middot;81). Baseline depression severity scores moderated the HIV+D plus EUC intervention effect, with the intervention having stronger effects for those with baseline scores in the severe range (≥20) than for those whose scores were in the moderate range (10-19) both at 3 and 12 months (p values for effect modification were <0middot;001 and 0middot;005, respectively). There was no evidence of effect modification by sex nor baseline HIV viral load. One participant in the HIV+D plus EUC group was hospitalised because of severe depression.INTERPRETATIONThe HIV+D plus EUC intervention had a significant and sustained effect on depression compared with EUC. This intervention offers a scalable approach to integrate","PeriodicalId":48725,"journal":{"name":"Lancet Hiv","volume":"85 1","pages":""},"PeriodicalIF":16.1,"publicationDate":"2026-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145994976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-15DOI: 10.1016/s2352-3018(26)00007-x
Ed Holt
{"title":"25 years of the Alliance for Public Health in Ukraine.","authors":"Ed Holt","doi":"10.1016/s2352-3018(26)00007-x","DOIUrl":"https://doi.org/10.1016/s2352-3018(26)00007-x","url":null,"abstract":"","PeriodicalId":48725,"journal":{"name":"Lancet Hiv","volume":"15 1","pages":""},"PeriodicalIF":16.1,"publicationDate":"2026-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145994977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-14DOI: 10.1016/s2352-3018(26)00002-0
Mauer Alexandre da Ascensão Gonçalves,Humberto Morais,Pedro Dos Reis Sousa E Almeida,Howard Lopes Ribeiro Junior
{"title":"Lessons from Brazil's elimination of vertical HIV transmission.","authors":"Mauer Alexandre da Ascensão Gonçalves,Humberto Morais,Pedro Dos Reis Sousa E Almeida,Howard Lopes Ribeiro Junior","doi":"10.1016/s2352-3018(26)00002-0","DOIUrl":"https://doi.org/10.1016/s2352-3018(26)00002-0","url":null,"abstract":"","PeriodicalId":48725,"journal":{"name":"Lancet Hiv","volume":"83 1","pages":""},"PeriodicalIF":16.1,"publicationDate":"2026-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145993048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-14DOI: 10.1016/s2352-3018(25)00242-5
Aditya H Gaur,Kristin Baltrusaitis,Edmund V Capparelli,John H Moye,Dwight E Yin,Gaerolwe Masheto,Sarah Buisson,Conn M Harrington,Mark A Marzinke,Elizabeth D Lowenthal,Rachel Scheckter,Andi Ace,Shawn Ward,Ryan Milligan,Kyle Whitson,Jenny Huang,S Y Amy Cheung,Brookie M Best,Ellen Townley,Gilly Roberts,Thomas N Kakuda,Eileen Birmingham,Sisinyana Ruth Mathiba,Linda Aurpibul,Violet Korutaro,Christiana Smith,Faeezah Patel,Evette Moodley,Carolyn Bolton-Moore, ,
BACKGROUNDCombined intramuscular long-acting cabotegravir-rilpivirine is the first long-acting combination antiretroviral therapy regimen approved for adults with HIV. The International Maternal Pediatric Adolescent AIDS Clinical Trials Network (IMPAACT 2017)-More Options for Children and Adolescents (MOCHA) study assessed safety, acceptability, tolerability, antiviral activity, and pharmacokinetics of these drugs in adolescents with HIV-1. Here we present secondary outcome data up to week 48.METHODSIn this phase 1/2, open-label, non-comparative, dose-finding trial conducted at 18 sites across Botswana, South Africa, Thailand, Uganda, and the USA, virologically suppressed (HIV-1 RNA <50 copies per mL) adolescents (aged 12-17 years; weight ≥35 kg) with HIV-1 switched prestudy antiretrovirals to 4 weeks of daily oral 30 mg cabotegravir and 25 mg rilpivirine, followed by 600 mg cabotegravir and 900 mg rilpivirine long-acting intramuscular (3 mL each) injections in the contralateral gluteus medius at week 4 and week 8, and then every 8 weeks. Secondary outcomes assessed here were grade 3 or worse adverse event, virological failure (including HIV-1 RNA ≥50 copies per mL and ≥200 copies per mL per the US Food and Drug Administration snapshot algorithm), and pharmacokinetic measures including cabotegravir and rilpivirine predose concentration assessment. This trial is registered with ClinicalTrials.gov, NCT03497676.FINDINGSBetween July 26, 2021, and Aug 27, 2022, 44 of 55 participants who had participated in cohort 1 and 100 of 115 screened study-naive participants were enrolled into cohort 2 of the study. 74 (51%) of 144 participants were female and 70 (49%) male, median age was 15 years (range 12-17), BMI 19·5 kg/m2 (16·0-34·3), weight 48·5 kg (35·2-100·9). 132 (92%) had vertical HIV acquisition. Of 144 enrolled participants, 142 received at least one injection, 140 completed week 48, and 140 received the expected seven injections through to week 48. Of 142 participants with at least one injection, 48 (34%) experienced injection-site reaction, mostly grade 1 resolving within 7 days. 43 (38%) of 140 participants experienced drug-related adverse events; two experienced grade 3 or worse adverse events (one abscess with pain 3 days after injection; one abscess 6 weeks after injection). The most common drug-related non-injection-site reaction adverse events were headache (three), rash (three), and nausea (two). After week 48, one participant experienced a grade 4 adverse event (anaphylaxis per site; post-injection reaction per Clinical Management Committee) that resolved but led to study drug discontinuation. No virological failures occurred through to week 48. Median week 48 observed predose concentrations were 2·77 μg/mL for cabotegravir (IQR 1·99-3·55) and 67·9 ng/mL for rilpivirine (52·8-82·4), approximating those in adults and exceeding the protein-adjusted IC90 of 0·166 μg/mL and 12 ng/mL, respectively.INTERPRETATIONWeek 48 data from the first virolo
{"title":"Safety, antiviral activity, and pharmacokinetics of long-acting injectable cabotegravir-rilpivirine in virologically suppressed adolescents living with HIV-1 (IMPAACT 2017/MOCHA): 48-week results of a multinational, phase 1/2, single-arm study.","authors":"Aditya H Gaur,Kristin Baltrusaitis,Edmund V Capparelli,John H Moye,Dwight E Yin,Gaerolwe Masheto,Sarah Buisson,Conn M Harrington,Mark A Marzinke,Elizabeth D Lowenthal,Rachel Scheckter,Andi Ace,Shawn Ward,Ryan Milligan,Kyle Whitson,Jenny Huang,S Y Amy Cheung,Brookie M Best,Ellen Townley,Gilly Roberts,Thomas N Kakuda,Eileen Birmingham,Sisinyana Ruth Mathiba,Linda Aurpibul,Violet Korutaro,Christiana Smith,Faeezah Patel,Evette Moodley,Carolyn Bolton-Moore, , ","doi":"10.1016/s2352-3018(25)00242-5","DOIUrl":"https://doi.org/10.1016/s2352-3018(25)00242-5","url":null,"abstract":"BACKGROUNDCombined intramuscular long-acting cabotegravir-rilpivirine is the first long-acting combination antiretroviral therapy regimen approved for adults with HIV. The International Maternal Pediatric Adolescent AIDS Clinical Trials Network (IMPAACT 2017)-More Options for Children and Adolescents (MOCHA) study assessed safety, acceptability, tolerability, antiviral activity, and pharmacokinetics of these drugs in adolescents with HIV-1. Here we present secondary outcome data up to week 48.METHODSIn this phase 1/2, open-label, non-comparative, dose-finding trial conducted at 18 sites across Botswana, South Africa, Thailand, Uganda, and the USA, virologically suppressed (HIV-1 RNA <50 copies per mL) adolescents (aged 12-17 years; weight ≥35 kg) with HIV-1 switched prestudy antiretrovirals to 4 weeks of daily oral 30 mg cabotegravir and 25 mg rilpivirine, followed by 600 mg cabotegravir and 900 mg rilpivirine long-acting intramuscular (3 mL each) injections in the contralateral gluteus medius at week 4 and week 8, and then every 8 weeks. Secondary outcomes assessed here were grade 3 or worse adverse event, virological failure (including HIV-1 RNA ≥50 copies per mL and ≥200 copies per mL per the US Food and Drug Administration snapshot algorithm), and pharmacokinetic measures including cabotegravir and rilpivirine predose concentration assessment. This trial is registered with ClinicalTrials.gov, NCT03497676.FINDINGSBetween July 26, 2021, and Aug 27, 2022, 44 of 55 participants who had participated in cohort 1 and 100 of 115 screened study-naive participants were enrolled into cohort 2 of the study. 74 (51%) of 144 participants were female and 70 (49%) male, median age was 15 years (range 12-17), BMI 19·5 kg/m2 (16·0-34·3), weight 48·5 kg (35·2-100·9). 132 (92%) had vertical HIV acquisition. Of 144 enrolled participants, 142 received at least one injection, 140 completed week 48, and 140 received the expected seven injections through to week 48. Of 142 participants with at least one injection, 48 (34%) experienced injection-site reaction, mostly grade 1 resolving within 7 days. 43 (38%) of 140 participants experienced drug-related adverse events; two experienced grade 3 or worse adverse events (one abscess with pain 3 days after injection; one abscess 6 weeks after injection). The most common drug-related non-injection-site reaction adverse events were headache (three), rash (three), and nausea (two). After week 48, one participant experienced a grade 4 adverse event (anaphylaxis per site; post-injection reaction per Clinical Management Committee) that resolved but led to study drug discontinuation. No virological failures occurred through to week 48. Median week 48 observed predose concentrations were 2·77 μg/mL for cabotegravir (IQR 1·99-3·55) and 67·9 ng/mL for rilpivirine (52·8-82·4), approximating those in adults and exceeding the protein-adjusted IC90 of 0·166 μg/mL and 12 ng/mL, respectively.INTERPRETATIONWeek 48 data from the first virolo","PeriodicalId":48725,"journal":{"name":"Lancet Hiv","volume":"269 1","pages":""},"PeriodicalIF":16.1,"publicationDate":"2026-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145993046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-14DOI: 10.1016/s2352-3018(25)00241-3
Elizabeth D Lowenthal,Jennifer Chapman,Kristin Baltrusaitis,Grace Kovic,Sanjna Merchant,Kaleb Branch,Chermiqua Tsosie,Martina Zapata Vaca,Barbara Heckman,Rodica M Van Solingen-Ristea,Conn M Harrington,Dwight E Yin,Ellen Townley,Michael Whitton,Allison L Agwu,Christiana Smith,Mary E Paul,Avy Violari,Evette Moodley,Maxensia Owor,Kulkanya Chokephaibulkit,Samantha Fry,Jennifer Jao,Charles D Mitchell,Sarah Buisson,Andi Ace,Irina Kolobova,Carolyn Bolton-Moore,Aditya H Gaur, ,
BACKGROUNDLong-acting cabotegravir and rilpivirine is the first intramuscular injectable antiretroviral treatment regimen recommended for maintenance of virological suppression in adults living with HIV-1. We report acceptability and tolerability outcomes in adolescents during 48 weeks of treatment with this regimen.METHODSIn this analysis of the phase 1/2, multicentre, open-label, non-comparative trial conducted at 18 sites across Botswana, South Africa, Thailand, Uganda, and the USA, 144 adolescents (weight ≥35 kg) with HIV-1 were enrolled to receive long-acting intramuscular cabotegravir and rilpivirine and 140 completed 48 weeks of treatment. Participant-reported acceptability and tolerability outcomes were a Faces Scale assessment of pain at each injection, preferred treatment method, and Quality of Life Inventory (PedsQL) at baseline and across 48 weeks of treatment for participants in Botswana, South Africa, Thailand, Uganda, and the USA. USA-based participants completed a Medication Satisfaction Questionnaire (SMSQc-Teen; after week 24), assessing their satisfaction with the all-intramuscular versus their previous oral regimen. A subset of eight adolescents and three parents or caregivers in the USA underwent in-depth interviews after a minimum of 24 weeks on study. This study is registered with ClinicalTrials.gov, NCT03497676.FINDINGSBetween July 26, 2021, and Aug 27, 2022, 44 of 55 adolescents who participated in cohort 1 and 100 of 115 screened study-naive adolescents were enrolled in cohort 2. 70 (49%) participants were male and 74 (51%) were female. 144 adolescents completed study questionnaires; 11 adolescents and parents completed in-depth interviews. At weeks 8, 24, and 48, 138 (97%) of 142, 139 (99%) of 141, and 140 (100%) of 140 participants, respectively, preferred intramuscular injections over oral treatment. Pain was more frequent with intramuscular rilpivirine than with cabotegravir (more pain than "hurts little bit" at all timepoints: 51-62% for rilpivirine vs 12-14% for cabotegravir). Health-related quality of life was high across all timepoints (overall median 94·6 [IQR 84·8-97·8] at baseline vs 93·5 [82·6-97·8] at 48 weeks). The 19 (100%) participants who completed the SMSQc-Teen reported higher satisfaction with the all-intramuscular regimen than with previous oral regimen. In the subset of individuals who underwent in-depth interviews, a prominent theme was reduced stress between parents and adolescents with the initiation of intramuscular antiretrovirals.INTERPRETATIONAcceptability and tolerability of intramuscular cabotegravir-rilpivirine remained high through to 48 weeks of treatment, suggesting that this long-acting intramuscular treatment approach is well received by diverse populations of adolescents with HIV across multiple settings.FUNDINGNational Institutes of Health and ViiV Healthcare.
{"title":"Acceptability and tolerability of long-acting injectable cabotegravir-rilpivirine in adolescents with HIV-1 (IMPAACT 2017/MOCHA): 48-week results of a multicentre, open-label, non-comparative phase 1/2 trial.","authors":"Elizabeth D Lowenthal,Jennifer Chapman,Kristin Baltrusaitis,Grace Kovic,Sanjna Merchant,Kaleb Branch,Chermiqua Tsosie,Martina Zapata Vaca,Barbara Heckman,Rodica M Van Solingen-Ristea,Conn M Harrington,Dwight E Yin,Ellen Townley,Michael Whitton,Allison L Agwu,Christiana Smith,Mary E Paul,Avy Violari,Evette Moodley,Maxensia Owor,Kulkanya Chokephaibulkit,Samantha Fry,Jennifer Jao,Charles D Mitchell,Sarah Buisson,Andi Ace,Irina Kolobova,Carolyn Bolton-Moore,Aditya H Gaur, , ","doi":"10.1016/s2352-3018(25)00241-3","DOIUrl":"https://doi.org/10.1016/s2352-3018(25)00241-3","url":null,"abstract":"BACKGROUNDLong-acting cabotegravir and rilpivirine is the first intramuscular injectable antiretroviral treatment regimen recommended for maintenance of virological suppression in adults living with HIV-1. We report acceptability and tolerability outcomes in adolescents during 48 weeks of treatment with this regimen.METHODSIn this analysis of the phase 1/2, multicentre, open-label, non-comparative trial conducted at 18 sites across Botswana, South Africa, Thailand, Uganda, and the USA, 144 adolescents (weight ≥35 kg) with HIV-1 were enrolled to receive long-acting intramuscular cabotegravir and rilpivirine and 140 completed 48 weeks of treatment. Participant-reported acceptability and tolerability outcomes were a Faces Scale assessment of pain at each injection, preferred treatment method, and Quality of Life Inventory (PedsQL) at baseline and across 48 weeks of treatment for participants in Botswana, South Africa, Thailand, Uganda, and the USA. USA-based participants completed a Medication Satisfaction Questionnaire (SMSQc-Teen; after week 24), assessing their satisfaction with the all-intramuscular versus their previous oral regimen. A subset of eight adolescents and three parents or caregivers in the USA underwent in-depth interviews after a minimum of 24 weeks on study. This study is registered with ClinicalTrials.gov, NCT03497676.FINDINGSBetween July 26, 2021, and Aug 27, 2022, 44 of 55 adolescents who participated in cohort 1 and 100 of 115 screened study-naive adolescents were enrolled in cohort 2. 70 (49%) participants were male and 74 (51%) were female. 144 adolescents completed study questionnaires; 11 adolescents and parents completed in-depth interviews. At weeks 8, 24, and 48, 138 (97%) of 142, 139 (99%) of 141, and 140 (100%) of 140 participants, respectively, preferred intramuscular injections over oral treatment. Pain was more frequent with intramuscular rilpivirine than with cabotegravir (more pain than \"hurts little bit\" at all timepoints: 51-62% for rilpivirine vs 12-14% for cabotegravir). Health-related quality of life was high across all timepoints (overall median 94·6 [IQR 84·8-97·8] at baseline vs 93·5 [82·6-97·8] at 48 weeks). The 19 (100%) participants who completed the SMSQc-Teen reported higher satisfaction with the all-intramuscular regimen than with previous oral regimen. In the subset of individuals who underwent in-depth interviews, a prominent theme was reduced stress between parents and adolescents with the initiation of intramuscular antiretrovirals.INTERPRETATIONAcceptability and tolerability of intramuscular cabotegravir-rilpivirine remained high through to 48 weeks of treatment, suggesting that this long-acting intramuscular treatment approach is well received by diverse populations of adolescents with HIV across multiple settings.FUNDINGNational Institutes of Health and ViiV Healthcare.","PeriodicalId":48725,"journal":{"name":"Lancet Hiv","volume":"144 1","pages":""},"PeriodicalIF":16.1,"publicationDate":"2026-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145993060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01DOI: 10.1016/s2352-3018(25)00360-1
The Lancet Hiv
{"title":"A sustainable future for HIV prevention.","authors":" The Lancet Hiv","doi":"10.1016/s2352-3018(25)00360-1","DOIUrl":"https://doi.org/10.1016/s2352-3018(25)00360-1","url":null,"abstract":"","PeriodicalId":48725,"journal":{"name":"Lancet Hiv","volume":"19 1","pages":"e1"},"PeriodicalIF":16.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145830347","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-20DOI: 10.1016/s2352-3018(25)00329-7
Christian Hoffmann, Jürgen K Rockstroh
{"title":"Standardisation of monitoring routines for new long-acting antiretrovirals in development","authors":"Christian Hoffmann, Jürgen K Rockstroh","doi":"10.1016/s2352-3018(25)00329-7","DOIUrl":"https://doi.org/10.1016/s2352-3018(25)00329-7","url":null,"abstract":"","PeriodicalId":48725,"journal":{"name":"Lancet Hiv","volume":"29 1","pages":""},"PeriodicalIF":16.1,"publicationDate":"2025-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145786006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：